Lead Product(s) : Perifosine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Pfizer Inc | Aeterna Zentaris
Deal Size : Inapplicable
Deal Type : Inapplicable
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 12, 2014
Lead Product(s) : Perifosine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Pfizer Inc | Aeterna Zentaris
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perifosine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2010
Lead Product(s) : Perifosine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perifosine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : University of Wisconsin, Madison | Duke University | National Comprehensive Cancer Network (Abbr.) | Pfizer Inc | Aeterna Zentaris
Deal Size : Inapplicable
Deal Type : Inapplicable
Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 15, 2010
Lead Product(s) : Perifosine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : University of Wisconsin, Madison | Duke University | National Comprehensive Cancer Network (Abbr.) | Pfizer Inc | Aeterna Zentaris
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perifosine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : SCRI Development Innovations, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Perifosine + Capecitabine for Colon Cancer Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 13, 2010
Lead Product(s) : Perifosine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : SCRI Development Innovations, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable